Aurinia Pharmaceuticals Inc (AUPH)vsAstraZeneca PLC (AZN)
AUPH
Aurinia Pharmaceuticals Inc
$15.72
+3.22%
HEALTHCARE · Cap: $2.02B
AZN
AstraZeneca PLC
$181.86
-0.54%
HEALTHCARE · Cap: $283.47B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 20161% more annual revenue ($60.44B vs $298.30M). AUPH leads profitability with a 100.0% profit margin vs 17.2%. AUPH trades at a lower P/E of 7.3x. AUPH earns a higher WallStSmart Score of 69/100 (B-).
AUPH
Strong Buy69
out of 100
Grade: B-
AZN
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AUPH.
Margin of Safety
+6.5%
Fair Value
$220.13
Current Price
$181.86
$38.27 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 65 in profit
Keeps 100 of every $100 in revenue as profit
Strong operational efficiency at 53.3%
Earnings expanding 56.3% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Areas to Watch
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AUPH
The strongest argument for AUPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 100.0% and operating margin at 53.3%. Revenue growth of 24.4% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : AUPH
The primary concerns for AUPH are Altman Z-Score.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
AUPH profiles as a growth stock while AZN is a mature play — different risk/reward profiles.
AUPH carries more volatility with a beta of 1.45 — expect wider price swings.
AUPH is growing revenue faster at 24.4% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AUPH scores higher overall (69/100 vs 62/100), backed by strong 100.0% margins and 24.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aurinia Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?